Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Diluted Average) (2024)

Contineum Therapeutics has reported Shares Outstanding (Diluted Average) over the past 1 years, most recently at $19.4 million for Q4 2024.

  • Quarterly results put Shares Outstanding (Diluted Average) at $19.4 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $19.4 million (changed N/A YoY), and the annual figure for FY2024 was $19.4 million, changed.
  • Shares Outstanding (Diluted Average) for Q4 2024 was $19.4 million at Contineum Therapeutics.
  • Over the last five years, Shares Outstanding (Diluted Average) for CTNM hit a ceiling of $19.4 million in Q4 2024 and a floor of $19.4 million in Q4 2024.